Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Novartis Venture Fund

Investor type Corporate Venture Capital
Founders Argeris Karabelas


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 245
Average round size
The average size of a deal this fund participated in
Portfolio companies 136
Rounds per year 9.42
Lead investments 45
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 59
Key employees 5
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical

In 1996 was created Novartis Venture Fund, which is appeared as VC. The main department of described VC is located in the Basel. The fund was located in Europe if to be more exact in Switzerland. Novartis Venture Fund appeared to be a CVC structure as part of the corporation.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Novartis Venture Fund, startups are often financed by SV Health Investors, Apple Tree Partners, ARCH Venture Partners. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, Venture Investors, Truffle Capital. In the next rounds fund is usually obtained by Sofinnova Investments, Astellas Venture Management, Venture Investors.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Medical Device, Life Science. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Alios BioPharma, Merus, Catalyst Biosciences The fund has exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.

The fund was created by Argeris Karabelas. The overall number of key employees were 5.

The fund is constantly included in 7-12 deals per year. The usual things for fund are deals in the range of 10 - 50 millions dollars. This Novartis Venture Fund works on 4 percentage points less the average amount of lead investments comparing to the other organizations. The higher amount of exits for fund were in 2014. The high activity for fund was in 2009. Despite it in 2019 the fund had an activity. The real fund results show that this VC is 7 percentage points more often commits exit comparing to other companies. When the investment is from Novartis Venture Fund the average startup value is 10-50 millions dollars.

Read more

Funds with similar focus

Funds from Switzerland
Funds with similar focus located in Switzerland:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


$154M25 Nov 2022 Beijing, Beijing, China


$59M22 Nov 2022 Munich, Bavaria, Germany

Capstan Therapeutics

Health Care
$102M14 Sep 2022 San Diego, California, United States

IGEM Therapeutics

02 Mar 2022 London, England, United Kingdom

Splice Bio

Life Science
$59M15 Feb 2022 Barcelona, Catalonia, Spain


Life Science
$111M20 Jan 2022 California, United States

IKAS Industrial Automation

$15M28 Dec 2021 Futian District, Guangdong Province, China


$119M16 Dec 2021 Basel-Country, Switzerland


$9M23 Nov 2021 London, England, United Kingdom
Immunitas Therapeutics Closes $58M in Series B Financing

– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.

GentiBio Raises $157M in Series A Financing

– GentiBio, Inc. from Boston develops engineered regulatory T cells (Tregs) therapies for immunology.
– Series A $157m round was led by Matrix Capital Management with participation from Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management, and Novartis Venture Fund.
– The company intends to use the funds to advance its potential functional cure for Type 1 Diabetes (T1D) to the clinic alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Novartis Venture Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: